Versartis
Pioneering advanced therapeutic proteins for endocrine disorders with innovative half-life extension technology.
General Information
BounceWatch is an independent company data service, not affiliated with Versartis. To contact Versartis, visit versartis.co.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About Versartis
Taxonomy: Therapeutic Proteins, Endocrine Disorders, XTEN Technology, Drug Development, Phase 1 Study, Growth Hormone Deficiency, Amunix, Index Ventures, Investment, Redwood City, California, Capital Efficiency, Healthcare Innovation
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $60.00M | - |
|
27 Sep 2016 |
| Post IPO Secondary | $75.00M | - |
|
20 Jan 2015 |
| Series E | $55.00M | 4 |
|
19 Feb 2014 |
| Series D | $20.00M | 6 |
|
08 Oct 2013 |
| Series C | $12.50M | 4 |
|
22 Jul 2013 |
| Series C | $25.00M | 4 |
|
15 Jan 2013 |
| Series B | $21.00M | 3 |
|
16 Feb 2011 |
| Series A | $11.00M | 1 |
|
02 Jun 2009 |
Versartis Alternatives & Competitors
View All Alternatives
Pioneering therapeutic solutions to treat alpha-1-antitrypsin deficiency since 2015 with expertise f...
Transforming Lives with Rare Focus
Pioneering therapeutic devices for emphysema and other breathing disorders, providing advanced treat...
FAQ About Versartis
Source: BounceWatch company record for Versartis, https://bouncewatch.com/company/versartis, updated 27 December 2024. When citing, please name BounceWatch and link this page.
